

**Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic
review and meta-analysis**

Baoqi Zeng¹, Le Gao², Qingxin Zhou³, Kai Yu¹, and Feng Sun⁴

¹ *Department of Science and Education, Peking University Binhai Hospital, Tianjin, China*

² *Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China*

³ *Tianjin Centers for Disease Control and Prevention, Tianjin, China*

⁴ *Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, Beijing, China*

Corresponding author: Kai Yu

Email: wzxkjk@126.com; Tel: +86-22-65665880

Address: Department of Science and Education, Peking University Binhai Hospital, Tianjin, China.

Alternative corresponding author: Feng Sun

Email: sunfeng@bjmu.edu.cn; Tel: +86-10-82801108

Address: Department of Epidemiology and Biostatistics, School of Public Health, Peking University

Health Science Centre, Beijing, China

ABSTRACT

Background. It was urgent and necessary to synthesize the evidence for vaccine effectiveness (VE) against SARS-CoV-2 variants of concern (VOC). We conducted a systematic review and meta-analysis to provide a comprehensive overview of the effectiveness profile of COVID-19 vaccines against VOC.

Methods. Published and preprinted randomized controlled trials (RCTs), cohort studies, and case-control studies that evaluated the VE against VOC (Alpha, Beta, Gamma, or Delta) were searched until 31 August 2021. Pooled estimates and 95% confidence intervals (CIs) were calculated using random-effects meta-analysis. VE was defined as (1–estimate).

Results. Seven RCTs (51,169 participants), 10 cohort studies (14,385,909 participants) and 16 case-control studies (734,607 cases) were included. Eight COVID-19 vaccines (mRNA-1273, BNT162b2, ChAdOx1, Ad26.COV2.S, NVX-CoV2373, BBV152, CoronaVac, and BBIBP-CorV) were included in this analysis. Full vaccination was effective against Alpha, Beta/Gamma, and Delta variants, with VE of 88.3% (95% CI, 82.4–92.2), 70.7% (95% CI, 59.9–78.5), and 71.6% (95% CI, 64.1–77.4), respectively. But partial vaccination was less effective, with VE of 59.0% (95% CI, 51.3–65.5), 49.3% (95% CI, 33.0–61.6), and 52.6% (95% CI, 43.3–60.4), respectively. mRNA vaccines seemed to have higher VE against VOC over others, significant interactions ($p_{\text{interaction}} < 0.10$) were observed between VE and vaccine type (mRNA vaccines vs. non-mRNA vaccines).

Conclusions. Full vaccination of COVID-19 vaccines is highly effective against Alpha variant, and moderate effective against Beta/Gamma and Delta variants. Partial vaccination has less VE against VOC. mRNA vaccines seem to have higher VE against Alpha, Beta/Gamma, and Delta variants over others.

Keywords. SARS-CoV-2; COVID-19; variants of concern; systematic review; vaccine effectiveness.

INTRODUCTION

Since emerging of coronavirus disease 2019 (COVID-19) caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019, more than 225 million cases and 4.6 million deaths have been documented worldwide as of 15 September 2021 [1]. COVID-19 vaccines have been rapidly developed, and proved to be highly effective in multiple randomized clinical trials (RCTs)[2-5] and observational studies [6-8]. Most current vaccines used SARS-CoV-2 spike protein as the key antigenic target based on the originally identified Wuhan lineage virus [9]. The B.1.1.7 (Alpha) variant was first identified from genomic sequencing of samples obtained from COVID-19 patients which accounted for an expanding proportion of cases in England in late 2020 [10]. Subsequently, the emergence of the B.1.351 (Beta) variant in South Africa and the P.1 (Gamma) variant in Brazil increased the COVID-19 pandemic. In December 2020, a novel SARS-CoV-2 variant, the B.1.617.2 (Delta) variant was first detected in India, causing a sharp increase in COVID-19 cases and deaths in India and surrounding countries [11]. The emerging Alpha, Beta, Gamma, and Delta variants were classified as variants of concern (VOC), which were associated with the transmission increasing, more severe disease situation (e.g., increased hospitalizations or deaths), significant reduction in neutralization by antibodies generated during previous infection or vaccination, reduced effectiveness of treatments or vaccines, or diagnostic detection failures [12-17]. The importance of vaccination programs and efficient public health measures will be increased if VOC have increased transmissibility or virulence.[18] It was urgent and necessary to synthesize evidence of the VE of COVID-19 vaccines against VOC. To our knowledge, there are some studies evaluating the VE of COVID-19 vaccines against VOC [19-22], but no relevant systematic review or meta-analysis has

been published to date. Therefore, to gain insight in the VE of COVID-19 vaccines against VOC, we conducted a comprehensive systematic review and meta-analysis including both RCTs and observational studies. This review of the VE of COVID-19 vaccines against VOC will support global response on public health measures and vaccination programs timely and evidence based.

METHODS

Data sources and searches

We conducted this systematic review according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines [23], the protocol was registered on PROSPERO (CRD42021273986). We searched for literature published on PubMed, Embase, Cochrane Library, and the ClinicalTrials.gov website on or before 4 August 2021. Meanwhile, we also searched the medRxiv website to include eligible preprints in the last three months (from 4 May 2021 to 4 August 2021). Keywords including “COVID-19”, “SARS-CoV-2”, “vaccine”, and “variant” were used to search, the detailed search strategy was shown in the Supplementary material. Additionally, we identified references by searching the reference lists of included studies and relevant reviews. Considering that the researches on COVID-19 vaccines were updated quickly, we researched literature before submission on 31 August 2021.

Selection of studies

We included randomized controlled trials (RCTs), cohort studies, and case-control studies that evaluated the efficacy or effectiveness of COVID-19 vaccines against VOC including B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta). Studies enrolling general population or special

populations (e.g., healthcare workers) aged 16 years or older were included. For studies that only reported VE against SARS-CoV-2 infections (without subgroup analysis of VOC), but the specific VOC accounted for 50% or more among positive tests, they were also included in the analysis. We excluded study protocols, editorials, comments, reviews, news, case reports, conference abstracts, animal studies, in vivo experiments, and analysis of antibody neutralization. Searches were limited to English articles. Preprints published in peer-reviewed journals were excluded. The primary outcome was the VE of full vaccination against VOC.

Data extraction

Two authors reviewed titles and abstracts independently to identify eligible studies that met pre-specified inclusion criteria and extracted data. When consensus was lacking, a third reviewer was consulted. The journal name, study type, study location, vaccine information, number of participants, characteristics of subjects, and outcomes were extracted from eligible studies. We extracted SARS-CoV-2 infection information if results on both SARS-CoV-2 infection and symptomatic infection were reported. The adjusted VE or estimates of effect size (relative risks, incidence rate ratios, or odds ratios) with corresponding 95% confidence intervals (CIs) was extracted with priority. The risk of bias of RCTs was assessed using the Cochrane Collaboration's tool [24, 25]. The risk of bias of cohort and case-control studies was assessed using the Newcastle-Ottawa scale (NOS) [26]. The NOS contains 8 categories relating to methodological quality, with a maximum of 9 points. A total score of 7–9 points is considered of good quality, while a score of 4–6 points of moderate quality, and a score of 1–3 points of low quality. Two investigators reviewed the studies and judged the risk of bias.

Statistical analysis

Pooled estimates and 95% CIs were calculated using DerSimonian and Laird random-effects meta-analysis [27]. Summary VE was defined as $(1 - \text{pooled estimate}) \times 100\%$. We performed subgroup analysis stratifying by study design, vaccine type, participant, and publication. P for the difference was calculated using random-effects meta-regression, a difference between the estimates of these subgroups was considered significant if $p_{\text{interaction}} < 0.10$ [28]. Statistical heterogeneity between the studies was assessed with the χ^2 test and the I^2 statistics. I^2 values of 25%, 50%, and 75% have been suggested to be indicators of low, moderate, and high heterogeneity, respectively [29]. All the analysis were performed with STATA 14.

RESULTS

Literature Research and Study characteristics

This systematic literature search identified 2226 publications and 596 preprints, after excluding duplicates and irrelevant papers, 78 published reports and 25 preprints were evaluated in full text for eligibility (Supplementary Figure 1). Finally, 33 articles (23 publications [6, 7, 19-22, 30-46] and 10 preprints [47-56]) were included in the present systematic review. There were different study designs for included studies, 7 RCTs (51,169 participants), 10 cohort studies (14,385,909 participants), and 16 case-control studies (734,607 cases). In total, 8 COVID-19 vaccines (mRNA-1273, BNT162b2, ChAdOx1, Ad26.COV2.S, NVX-CoV2373, BBV152, CoronaVac and BBIBP-CorV) and 4 VOC (Alpha, Beta, Gamma and Delta) were included in this study. BNT162b2 and mRNA-1273 are mRNA vaccines, CoronaVac, BBV152 and BBIBP-CorV are inactivated vaccines, Ad26.COV2.S and

ChAdOx1 are non-replicating vector vaccines, and NVX-CoV2373 is a protein subunit vaccine. Only Ad26.COV2.S is a single-dose vaccine, therefore a one-dose regimen is regarded as full vaccination. Characteristics of individual studies are summarized in Table 1.

Risk of Bias

All the RCTs were assessed as some concerns for overall risk-of-bias judgment. Seven of 10 cohort studies were judged as good quality, and the remaining 3 studies were moderate quality. For 16 case-control studies, 13 were considered as good quality and 3 were moderate quality. The detailed risk of bias assessment is available in online Supplementary Table 1–3.

Vaccine Effectiveness of COVID-19 Vaccines against B.1.1.7 (Alpha) Variant

Two RCTs [22, 44], 5 cohort studies [6, 7, 34, 38, 52] and 11 case-control studies [20, 30, 31, 33, 35, 39, 40, 43, 46, 47, 51] had evaluated the VE of COVID-19 vaccines against the Alpha variant. One cohort study [52] and 2 case-control studies [47, 51] were preprints on the medRxiv website. Four COVID-19 vaccines (mRNA-1273, NVX-CoV2373, ChAdOx1 and BNT162b2) were included in this analysis. Three studies enrolled healthcare workers [6, 33, 34], two enrolled participants aged 70 or older [30, 35], and the others enrolled the general population. Characteristics of individual studies and VE for Alpha variant are summarized in Figure 1 and Supplementary Table 4.

The summary VE of full vaccination against the Alpha variant was 88.3% (95% CI, 82.4–92.2) (Table 2). Subgroup analysis by study design showed that VE was 79.4% (56.2–90.3) in 2 RCTs, 88.3% (95% CI, 70.9–95.3) in 5 cohort studies and 88.7% (95% CI, 84.2–92.0) in 10 case-control studies ($p_{\text{interaction}} = 0.435$). Subgroup analysis of vaccine type showed that VE was 90.9% (95% CI, 86.2–94.0)

for mRNA vaccines in 15 study groups, 73.8% (95% CI, 69.8–77.4) for non-replicating vector vaccine in 5 study groups, 86.3% (95% CI, 71.3–93.5) for protein subunit vaccine in 1 study group, and 82.0% (95% CI, 27.0–95.0) for combined vaccines (BNT162b2/ChAdOx1) in 1 study group ($p_{\text{interaction}} = 0.084$). And we detected a significant interaction ($p_{\text{interaction}} = 0.009$) between VE and vaccine type (mRNA vaccines vs. non-mRNA vaccines), the VE of mRNA vaccines seemed to be higher than others. The results of subgroup analysis for participant and publication were in Table 2.

The summary VE of partial vaccination against the Alpha variant (Table 2) was 59.0% (95% CI, 51.3–65.5). Subgroup analysis of study design showed that VE was 53.3% (95% CI, 40.0–63.7) in 4 cohort studies and 60.6% (95% CI, 51.4–68.1) in 10 case-control studies ($p_{\text{interaction}} = 0.565$). Subgroup analysis by vaccine type showed that VE was 61.5% (95% CI, 51.9–69.3) for mRNA vaccines in 14 study groups, 56.9% (95% CI, 41.7–68.1) for non-replicating vector vaccine in 4 study groups, and 21.0% (95% CI, -3.0–39.0) for combined vaccines (BNT162b2/ChAdOx1) in 1 study group ($p_{\text{interaction}} = 0.687$).

Vaccine Effectiveness of COVID-19 Vaccines against B.1.351 (Beta) and P.1 (Gamma) Variants

Four RCTs [21, 39, 45, 56], 1 cohort study [50], and 4 case-control studies [40, 43, 46, 47] had evaluated the VE of COVID-19 vaccines against the Beta variant. One cohort study [36] and 3 case-control studies [32, 35, 49] had evaluated the VE of COVID-19 vaccines against the Gamma variant. Both Beta and Gamma have N501Y and E484K mutations, 2 studies used a combined Beta/Gamma group because of insufficient specimens [31, 51]. One RCT [56] and 3 case-control studies [31, 49, 51] were preprints on the medRxiv website. Six COVID-19 vaccines (mRNA-1273, BNT162b2, NVX-CoV2373, ChAdOx1, CoronaVac and Ad26.COV2.S) were included in this

analysis. Single-dose Ad26.COV2.S was considered a full vaccination. For the study population, 1 study enrolled health care workers [49], 2 studies enrolled participants aged 70 or older [32, 35], 2 studies enrolled participants from long-term care homes [36, 50], and the others enrolled the general population. Characteristics of individual studies and VE for Beta and Gamma variants are summarized in Figure 2 and Supplementary Table 5.

The summary VE of full vaccination against Beta variant were 73.2% (95% CI, 61.0–81.5) (Table 2). Subgroup analysis by study design showed that VE for Beta variant was 70.2% (95% CI, 18.8–89.1) in 4 RCTs, 80.2% (95% CI, 71.1–86.4) in 4 case-control studies, and 49.0% (95% CI, 14.0–69.0) in 1 cohort study ($p_{\text{interaction}} = 0.933$). Subgroup analysis of vaccine type showed that VE was 80.3% (95% CI, 69.7–87.1) for mRNA vaccines in 6 studies, 44.9% (95% CI, -34.5–77.4) for non-replicating vector vaccines in 2 studies, and 51.1% (95% CI, -0.6–76.2) for protein subunit vaccine in 1 study ($p_{\text{interaction}} = 0.214$). The summary VE of partial vaccination against Beta variant was 41.9% (95% CI, 3.3–65.2) in four studies.

The summary VE of full vaccination against Gamma variant was 47.5% (95% CI, 40.1–54.0) in 4 study groups, and partial vaccination against Gamma variant was 40.6% (95% CI, -31.1–73.1) in 2 study groups (Table 2). When Beta/Gamma variant was treated as one group, the summary VE of full vaccination was 70.7% (95% CI, 59.9–78.5) in 15 study groups, and partial vaccination against Gamma variant was 49.3% (95% CI, 33.0–61.6) in 10 study groups. Subgroup analysis of vaccine types showed that VE of full vaccination against Beta/Gamma was 78.3% (95% CI, 69.4–84.6) for mRNA vaccines in 10 study groups and 47.3% (95% CI, 35.4–57.0) for non-mRNA vaccines in 5 study groups ($p_{\text{interaction}} = 0.042$), the VE for mRNA vaccines seemed to be higher than others. The results are in Table 2.

Vaccine Effectiveness of COVID-19 Vaccines against B.1.617.2 (Delta) Variant

One RCT [48], 4 cohort studies [41, 42, 52, 54] and 7 case-control studies [20, 37, 39, 47, 51, 53, 55] had evaluated the VE of COVID-19 vaccines against the Delta variant. Seven studies are preprints on the medRxiv website [47, 48, 51-55]. Six COVID-19 vaccines (mRNA-1273, BBV152, ChAdOx1, BNT162b2, CoronaVac and BBIBP-CorV) were included in this analysis. Two studies enrolled health care workers or frontline workers [41, 53], 1 study enrolled participants in the nursing home [42], and the others enrolled the general population. Characteristics of individual studies and VE for Delta variant are summarized in Figure 3 and Supplementary Table 6.

The summary VE of full vaccination against the Delta variant was 71.6% (95% CI, 64.1–77.4) (Table 2). Subgroup analysis of study design showed that VE for Delta variant was 65.2% (95% CI, 33.1–83.0) in 1 RCT, 74.8% (95% CI, 65.3–81.8) in 7 case-control studies, and 66.2% (95% CI, 51.3–76.5) in 4 cohort studies ($p_{\text{interaction}} = 0.256$). Subgroup analysis by vaccine type showed that VE was 75.6% (95% CI, 64.9–83.1) for mRNA vaccines in 11 study groups, 64.4% (95% CI, 59.8–68.4) for non-replicating vector vaccine in 4 study groups, and 62.5% (95% CI, 37.7–77.5) for inactivated vaccines in 2 study groups ($p_{\text{interaction}} = 0.124$). An interaction ($p_{\text{interaction}} = 0.097$) between VE and vaccine type (mRNA vaccines vs. non-mRNA vaccines) was found, the VE for mRNA vaccines seemed to be higher than others.

The summary VE of partial vaccination against the Delta variant was 52.6% (95% CI, 43.3–60.4) (Table 2). Subgroup analysis for study design showed that VE for Delta variant was 59.5% (95% CI, 44.1–70.7) in 1 cohort study, and 49.3% (95% CI, 39.0–57.9) in 7 case-control studies ($p_{\text{interaction}} = 0.469$). Subgroup analysis of vaccine type showed that VE was 60.5% (95% CI, 49.2–69.4) for

mRNA vaccines in 9 study groups, 38.2% (95% CI, 24.6–49.3) for non-replicating vector vaccine in 5 study groups, and 13.8% (95% CI, 60.2–54.8) for inactivated vaccines in 1 study group ($p_{\text{interaction}} = 0.038$). The VE for mRNA vaccines seemed to be higher than others.

DISCUSSION

We conducted this systematic review and meta-analysis to synthesize evidence on the VE of COVID-19 vaccines against VOC during the pandemic. This study has four main findings. First, full vaccination of COVID-19 vaccines was effective against Alpha, Beta/Gamma and Delta variants, with the VE of 88.3% (95% CI, 82.4–92.2), 70.7% (95% CI, 59.9–78.5) and 71.6% (95% CI, 64.1–77.4), respectively. Second, partial vaccination has lower VE against Alpha, Beta/Gamma and Delta variants, with the VE of 59.0% (95% CI, 51.3–65.5), 49.3% (95% CI, 33.0–61.6), 52.6% (95% CI, 43.3–60.4), respectively. Third, mRNA vaccines (BNT162b2 or mRNA-1273) seemed to have higher VE against VOC over other vaccines. Fourth, more evidence was needed to evaluate the VE of COVID-19 against the Gamma and Delta variants. To our knowledge, our study is the first comprehensive systematic review and meta-analysis to characterize the VE of COVID-19 vaccines against VOC.

The evidence for the Gamma variant was insufficient, only four studies were included [32, 35, 36, 49]. One study [36] enrolled residents or staff in long term care homes and two [32, 35] enrolled older adults aged 70 years and older, which reflected the VE against Gamma variant for elderly and frail people. The remaining one study evaluating the CoronaVac vaccine against the Gamma variant enrolled healthcare workers, but unmeasured confounding which led to downward bias in the VE estimate was reported [49].

The main results in this study were in consistent with a recent meta-analysis for neutralizing

antibodies against SARS-CoV-2 variants, which showed that Alpha, Beta, Gamma and Delta variants significantly escaped natural-infection-mediated neutralization, with an average of 1.4-fold, 4.1-fold, 1.8-fold, and 3.2-fold reduction in live virus neutralization assay [57]. Despite the reduction in neutralization titers against Alpha variant, they remain robust, and there is no evidence of vaccine escape in one study [58]. Escape of Beta variant from neutralization by convalescent plasma and vaccine-induced sera was observed in some studies [12, 59, 60]. Although neutralization titers against Gamma variant are reduced, it is hoped that immunization with vaccines designed against parent strains will protect Gamma variant infection [61]. The Delta variant escapes neutralization by some antibodies that target the receptor-binding domain or N-terminal domain, the neutralization titers against Delta was three to five folds than Alpha variant when two-dose of the vaccine administrated.[14] This study also supports the two-dose vaccine regimen recommended by the FDA and EMA, which is consistent with an in-vitro study for SARS-CoV-2 variants of concern [62].

This review included 3 study designs evaluating 8 COVID-19 vaccines against 4 VOC in different populations. There is high heterogeneity between studies, and high statistical heterogeneity is also observed in most analysis. Other factors like the definition of outcomes (all SARS-CoV-2 or symptomatic infection), days after vaccination and participant's characteristics (e.g., age and race) may also contribute to the heterogeneity. Therefore, we mainly performed narrative descriptive synthesis.

This systematic review and meta-analysis has some limitations. First, 21% of studies (7 of 33) are nonrandomized. The imbalance between groups in observational studies is a concern, so potential selection bias may be existent. Second, 30% of studies (10 of 33) are preprints and have not been certified by peer review. We may not identify errors in data analysis or reporting due to the lack of a

rigorous vetting process. Third, although we performed qualitative analysis by different stratifications, heterogeneity was still high in most quantitative analysis. Forth, VE against hospitalization or death related to VOC is not included in our analysis. Finally, the evidence of COVID-19 vaccines against Gamma and Delta variants is not enough, more research is needed in the future.

CONCLUSION

Full vaccination of COVID-19 vaccines is highly effective against Alpha variant, and moderate effective against Beta/Gamma and Delta variant. Partial vaccination has less effectiveness against all VOC. Therefore, full vaccination is recommended against variants of SARS-CoV-2. mRNA vaccines (BNT162b2 or mRNA-1273) seem to have higher VE against Alpha, Beta/Gamma, or Delta over other vaccines, but more evidence is needed to confirm this finding.

Notes

Author contributions.

KY and FS conceived the study. BZ and KY designed the study. BZ, LG and QZ undertook the literature review and extracted the data. BZ and QZ coded the statistical analysis, figures, and appendix. BZ and LG interpreted the data and wrote the first draft of the manuscript. All authors reviewed and revised subsequent drafts and approved the final version.

Financial support.

No sources of funding are declared for this manuscript.

Potential conflicts of interest.

The authors declare that they have no conflicts of interest.

References

1. World Health Organization. WHO coronavirus disease (COVID-19) dashboard. Available at: <https://www.who.int>. Accessed 15 September 2021.
2. Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *Lancet* **2021**; 397(10277): 881-91.
3. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *New Engl J Med* **2021**; 384(5): 403-16.
4. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New Engl J Med* **2020**; 383(27): 2603-15.
5. Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. *Lancet* **2021**; 397(10275): 671-81.
6. Hall VJ, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. *Lancet* **2021**; 397(10286): 1725-35.
7. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *New Engl J Med* **2021**; 384(15): 1412-23.
8. Thompson MG, Burgess JL, Naleway AL, et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection

- Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. *MMWR-Morbidity and Mortality Weekly Report* **2021**; 70(13): 495-500.
9. Le TT, Cramer JP, Chen R, Mayhew S. Evolution of the COVID-19 vaccine development landscape. *Nature reviews Drug discovery* **2020**; 19(10): 667-8.
 10. Rambaut A, Loman N, Pybus O, et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. **2020**. Available at: <https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563>. Accessed 15 September 2021.
 11. European Centre for Disease Prevention and Control. Threat assessment brief: emergence of SARS-CoV-2 B.1.617 variants in India and situation in the EU/EEA. **2021**. Available at: <https://www.ecdc.europa.eu/en/publications-data/threat-assessment-emergence-sars-cov-2-b1617-variants>. Accessed 15 September 2021.
 12. Hoffmann M, Arora P, Groß R, et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. *Cell* **2021**; 184(9): 2384-93.e12.
 13. Garcia-Beltran WF, Lam EC, St Denis K, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. *Cell* **2021**; 184(9): 2372-83.e9.
 14. Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature* **2021**.
 15. Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. *BMJ (Clinical research ed)* **2021**; 372: n579.

16. Walensky RP, Walke HT, Fauci AS. SARS-CoV-2 Variants of Concern in the United States-Challenges and Opportunities. *JAMA* **2021**; 325(11): 1037-8.
17. CDC. SARS-CoV-2 Variant Classifications and Definitions. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html>. Accessed 15 September 2021.
18. Krause PR, Fleming TR, Longini IM, et al. SARS-CoV-2 Variants and Vaccines. *New Engl J Med* **2021**; 385(2): 179-86.
19. Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. *New Engl J Med* **2021**; 384(20): 1899-909.
20. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *New Engl J Med* **2021**.
21. Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. *New Engl J Med* **2021**; 385(7):585-94.
22. Emary KRW, Golubchik T, Aley PK, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. *Lancet* **2021**; 397(10282): 1351-62.
23. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* **2009**; 339: b2535.
24. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* **2011**; 343: d5928.
25. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* **2019**; 366: 14898.

26. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. **2008**. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 15 September 2021.
27. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* **1986**; 7(3): 177-88.
28. Richardson M, Garner P, Donegan S. Interpretation of subgroup analyses in systematic reviews: A tutorial. *Clin Epidemiol Glob* **2019**; 7(2): 192-8.
29. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* **2003**; 327(7414): 557-60.
30. Bernal JL, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study. *BMJ* **2021**; 373:n1088
31. Chung H, He S, Nasreen S, et al. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. *BMJ* **2021**; 374: n1943.
32. Ranzani OT, Hitchings MDT, Dorion M, et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. *BMJ* **2021**; 374: n2015.
33. Carazo S, Talbot D, Boulianne N, et al. Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada. *Clin Infect Dis* **2021**.

34. Lumley SF, Rodger G, Constantinides B, et al. An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status. *Clin Infect Dis* **2021**.
35. Skowronski DM, Setayeshgar S, Zou M, et al. Single-dose mRNA vaccine effectiveness against SARS-CoV-2, including Alpha and Gamma variants: a test-negative design in adults 70 years and older in British Columbia, Canada. *Clin Infect Dis* **2021**.
36. Williams C, Al-Bargash D, Macalintal C, et al. COVID-19 Outbreak Associated with a SARS-CoV-2 P.1 Lineage in a Long-Term Care Home after Implementation of a Vaccination Program - Ontario, April-May 2021. *Clin Infect Dis* **2021**.
37. Li XN, Huang Y, Wang W, et al. Efficacy of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study. *Emerg Microbes Infec* **2021**: 1-32.
38. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *Lancet* **2021**; 397(10287): 1819-29.
39. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *Lancet* **2021**; 397(10293): 2461-2.
40. Charmet T, Schaeffer L, Grant R, et al. Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France. *Lancet Reg Health Eur* **2021**; 8:

100171.

41. Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K. Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance - Eight U.S. Locations, December 2020-August 2021. *MMWR-Morbid Mortal W* **2021**; 70(34): 1167-9.
42. Nanduri S, Pilishvili T, Derado G, et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021. *MMWR-Morbid Mortal W* **2021**; 70(34): 1163-6.
43. Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. *New Engl J Med* **2021**; 385(2): 187-9.
44. Heath PT, Galiza EP, Baxter DN, et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. *New Engl J Med* **2021**.
45. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *New Engl J Med* **2021**; 384(23): 2187-201.
46. Chemaitelly H, Yassine HM, Benslimane FM, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. *Nat Med* **2021**; 27(9):1614-1621
47. Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. *medRxiv* **2021**: 2021.08.25.21262584.
48. Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot to lot immunogenicity of an

- inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial. medRxiv **2021**: 2021.06.30.21259439.
49. Hitchings MDT, Ranzani OT, Scaramuzzini Torres MS, et al. Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study. medRxiv **2021**: 2021.04.07.21255081.
50. Lefèvre B, Tondeur L, Madec Y, et al. Impact of B.1.351 (beta) SARS-CoV-2 variant on BNT162b2 mRNA vaccine effectiveness in long-term care facilities of eastern France: a retrospective cohort study. medRxiv **2021**: 2021.07.28.21261285.
51. Nasreen S, Chung H, He S, et al. Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada. medRxiv **2021**: 2021.06.28.21259420.
52. Pouwels KB, Pritchard E, Matthews PC, et al. Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. medRxiv **2021**: 2021.08.18.21262237.
53. Pramod S, Govindan D, Ramasubramani P, et al. Effectiveness of Covishield vaccine in preventing Covid-19 – A test-negative case-control study. medRxiv **2021**: 2021.07.19.21260693.
54. Puranik A, Lenehan PJ, Silvert E, et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. medRxiv **2021**. 2021.08.06.21261707
55. Tang P, Hasan MR, Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar. medRxiv **2021**: 2021.08.11.21261885.

56. Thomas SJ, Moreira ED, Kitchin N, et al. Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. medRxiv **2021**: 2021.07.28.21261159.
57. Chen X, Chen Z, Azman AS, et al. Neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination: a systematic review and pooled meta-analysis. Clin Infect Dis **2021**.
58. Supasa P, Zhou D, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell **2021**; 184(8): 2201-11.e7.
59. Zhou D, Dejnirattisai W, Supasa P, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell **2021**; 184(9): 2348-61.e6.
60. Li Q, Nie J, Wu J, et al. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell **2021**; 184(9): 2362-71.e9.
61. Dejnirattisai W, Zhou D, Supasa P, et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell **2021**; 184(11): 2939-54.e9.
62. Skelly DT, Harding AC, Gilbert-Jaramillo J, et al. Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. Nat Commun **2021**; 12(1): 5061.

Table 1 Study characteristics and participants demographics

First Author	Journal	Study design	VOC	Vaccine	Country	Population Characteristics	Participants
Shinde [19]	N Engl J Med	RCT (phase 2a/b)	Beta	NVX-CoV2373	South Africa	GP; Age: 18-84	4,387
Madhi [21]	N Engl J Med	RCT (phase 3)	Beta	ChAdOx1	South Africa	GP; Age: 18-65	1,467
Heath [44]	N Engl J Med	RCT (phase 3)	Alpha	NVX-CoV2373	UK	GP; Age: 18-84	14,039
Sadoff [45]	N Engl J Med	RCT (phase 3)	Beta	Ad26.COV2.S	South Africa	GP; Age: ≥18	4,969
Emary [22]	Lancet	RCT (phase 2/3)	Alpha	ChAdOx1	UK	GP; Age: ≥18	8,534
Ella [48]	<i>Preprint</i>	RCT (phase 3)	Delta	BBV152	India	GP; Age: 18-98	16,973
Thomas [56]	<i>Preprint</i>	RCT (phase 2/3)	Beta	BNT162b2	South Africa	GP; Age: ≥16	800
Lopez Bernal [20]	N Engl J Med	TNCC	Alpha & Delta	BNT162b2 or ChAdOx1	UK	GP; Age: ≥16	19,109 cases
Abu-Raddad [43]	N Engl J Med_ Letter	TNCC	Alpha & Beta	BNT162b2	Qatar	GP; Age: 33 (22-40) ^a	35,979 cases
Sheikh [39]	Lancet_ Correspondence	TNCC	Alpha & Delta	BNT162b2 or ChAdOx1	UK	GP	19,543 cases
Chemaitelly [46]	Nat Med	TNCC	Alpha & Beta	mRNA-1273	Qatar	GP; Age: 32 (25-39) ^a	66,042 cases
Bernal [30]	BMJ	TNCC	Alpha	BNT162b2	UK	Older adults; Age: ≥70	3,034 cases
Chung [31]	BMJ	TNCC	Alpha & Beta/Gamma	BNT162b2 and mRNA-1273	Canada	GP; ≥16	324,033 cases
Ranzani [32]	BMJ	TNCC	Gamma	CoronaVac	Brazil	Older adults; ≥70	43,774 cases
Skowronski [35]	Clin Infect Dis	TNCC	Alpha & Gamma	BNT162b2 (85%) and mRNA-1273 (15%)	Canada	Older adults; ≥70	483 cases
Carazo [33]	Clin Infect Dis	TNCC	Alpha	BNT162b2 and mRNA-1273	Canada	HCWs; Age: 18-74	901 cases
Li [37]	Emerg Microbes Infect	TNCC	Delta	CoronaVac and BBIBP-CorV	China	GP; Age: 18-59	74 cases
Charmet [40]	Lancet Reg Health Eur	Case-control	Alpha & Beta/Gamma	BNT162b2 and mRNA-1273	France	GP; Age: ≥20	33,863 cases
Nasreen [51]	<i>Preprint</i>	TNCC	Alpha & Beta/Gamma	BNT162b2, mRNA-1273, or	Canada	GP; Age: ≥16	40,828 cases

			& Delta	ChAdOx1			
Hitchings [49]	<i>Preprint</i>	TNCC	Gamma	CoronaVac	Brazil	HCWs; Age: ≥18	418 cases
Tang [55]	<i>Preprint</i>	TNCC	Delta	BNT162b2 or mRNA-1273	Qatar	GP; Age: 31 (24-37) ^a	1,731 cases
Chemaitelly [47]	<i>Preprint</i>	TNCC	Alpha & Beta & Delta	BNT162b2	Qatar	GP; Age: 32 (23-39) ^a	144,075 cases
Pramod [53]	<i>Preprint</i>	TNCC	Delta	ChAdOx1-S	India	HCWs; Age: 34 (28-43) ^a	720 cases
Hall [6]	Lancet	Prospective cohort	Alpha	BNT162b2 (94%) and ChAdOx1 (6%)	UK	HCWs; Age: ≥18	23,324
Haas [38]	Lancet	Retrospective cohort	Alpha	BNT162b2	Israel	GP; Age: ≥16	6,538,911
Dagan [7]	N Engl J Med	Retrospective cohort	Alpha	BNT162b2	Israel	GP; Age: ≥16	1,193,236
Lumley [34]	Clin Infect Dis	Retrospective cohort	Alpha	BNT162b2 and ChAdOx1	UK	HCWs; Age: 39(30-50) ^a	13,109
Williams [36]	Clin Infect Dis	Retrospective cohort	Gamma	mRNA-1273	Canada	Residents and staff of LTCH	143
Nanduri [42]	Morb Mortal Wkly Rep	Retrospective cohort	Delta	mRNA-1273 or BNT162b2	US	Nursing home residents	5,965,607
Fowlkes [41]	Morb Mortal Wkly Rep	Retrospective cohort	Delta	mRNA-1273 (33%) and BNT162b2 (65%)	US	Frontline workers	2,840
Puranik [54]	<i>Preprint</i>	Retrospective cohort	Delta (July)	mRNA-1273 or BNT162b2	US	GP; Age: ≥18	67,469
Lefèvre [50]	<i>Preprint</i>	Retrospective cohort	Beta	BNT162b2	France	Residents of LTCH; Age: 89 (83-92) ^a	378
Pouwels [52]	<i>Preprint</i>	Retrospective cohort	Alpha & Delta	BNT162b2 or ChAdOx1 or mRNA-1273	UK	GP; Age: ≥18	580,892

Abbreviations: VOC, variants of concern; HCWs, healthcare workers; TNCC, Test-negative case-control; LTCH, long term care homes; GP, general population; RCT, randomized controlled trial.

^aMedian age (interquartile range)

Table 2. Meta-analysis and subgroup analysis for VE of COVID-19 against VOC

Covariates	Subgroup	Study groups	Pooled estimates	I^2	p (ES=1)	VE% (95% CI)	$p_{\text{interaction}}$
Alpha (full vaccination)							
All		22	0.117 (0.078–0.176)	98%	< 0.001	88.3 (82.4–92.2)	
Study design	RCT	2	0.206 (0.097–0.438)	58%	< 0.001	79.4 (56.2–90.3)	0.435
	Case-control	14	0.113 (0.080–0.158)	94%	< 0.001	88.7 (84.2–92.0)	
	Cohort	6	0.117 (0.047–0.291)	97%	< 0.001	88.3 (70.9–95.3)	
Vaccine type	mRNA vaccines	15	0.091 (0.060–0.138)	97%	< 0.001	90.9 (86.2–94.0)	0.084
	Non-replicating vector vaccine	5	0.262 (0.226–0.302)	0%	< 0.001	73.8 (69.8–77.4)	
	Protein subunit vaccine	1	0.137 (0.065–0.287)	–	0.012	86.3 (71.3–93.5)	
	mRNA vaccines or Non-replicating vector vaccine	1	0.180 (0.050–0.730)	–	< 0.001	82.0 (27.0–95.0)	
	<i>Non-mRNA vaccines</i>	7	0.254 (0.221–0.293)	–	< 0.001	74.6 (70.7–77.9)	
Participant	GP	18	0.119 (0.075–0.186)	98%	< 0.001	88.1 (81.4–92.5)	0.822
	HCWs	3	0.096 (0.058–0.158)	8%	< 0.001	90.4 (84.2–94.2)	
	Older	1	0.100 (0.061–0.163)		< 0.001	90.0 (83.7–93.9)	
Publication	Published	15	0.101 (0.063–0.163)	98%	< 0.001	89.9 (83.7–93.7)	0.143
	Preprint	4	0.175 (0.105–0.292)	89%	< 0.001	82.5 (70.8–89.5)	
Alpha (partial vaccination)							
All		19	0.410 (0.345–0.487)	97%	< 0.001	59.0 (51.3–65.5)	
Study design	Case-control	14	0.394 (0.319–0.486)	98%	< 0.001	60.6 (51.4–68.1)	0.565
	Cohort	5	0.467 (0.363–0.600)	88%	0.161	53.3 (40.0–63.7)	
Vaccine type	mRNA vaccines	14	0.385 (0.307–0.481)	97%	< 0.001	61.5 (51.9–69.3)	0.687
	Non-replicating vector vaccine	4	0.431 (0.319–0.583)	97%	< 0.001	56.9 (41.7–68.1)	
	mRNA vaccines or Non-replicating vector vaccine	1	0.790 (0.610–1.030)	–	0.078	21.0 (–3.0–39.0)	
Participant	GP	14	0.393 (0.321–0.482)	98%	< 0.001	60.7 (51.8–67.9)	0.568

	HCWs	3	0.461 (0.268–0.793)	91%	< 0.001	53.9 (20.7–73.2)	
	Older	2	0.463 (0.243–0.883)	94%	0.019	53.7 (11.7–75.7)	
Publication	Published	13	0.477 (0.412–0.552)	94%	< 0.001	52.3 (44.8–58.8)	0.091
	Preprint	6	0.306 (0.242–0.388)	93%	< 0.001	69.4 (61.2–75.8)	
Beta (full vaccination)							
	All	9	0.268 (0.185–0.390)	85%	< 0.001	73.2 (61.0–81.5)	
Study design	RCT	4	0.298 (0.109–0.812)	85%	0.018	70.2 (18.8–89.1)	0.933
	Case-control	4	0.198 (0.136–0.289)	83%	< 0.001	80.2 (71.1–86.4)	
	Cohort	1	0.510 (0.310–0.860)	51%	0.010	49.0 (14.0–69.0)	
Vaccine type	mRNA vaccines	6	0.197 (0.129–0.303)	86%	< 0.001	80.3 (69.7–87.1)	0.214
	Non-replicating vector vaccine	2	0.551 (0.226–1.345)	77%	0.191	44.9 (–34.5–77.4)	
	Protein subunit vaccine	1	0.489 (0.238–1.006)	–	0.052	51.1 (–0.6–76.2)	
Participant	GP	8	0.246 (0.166–0.365)	85%	< 0.001	75.4 (63.5–83.4)	0.524
	LTCH/Older	1	0.510 (0.310–0.860)	–	0.010	49.0 (14.0–69.0)	
Publication	Published	7	0.303 (0.188–0.490)	86%	< 0.001	69.7 (51.0–81.2)	0.247
	Preprint	2	0.059 (0.002–1.395)	91%	p = 0.079	94.1 (–39.8–99.8)	
Beta (partial vaccination)							
	All	4	0.581 (0.348–0.967)	98%	0.037	41.9 (3.3–65.2)	
Gamma (full vaccination)							
	All	4	0.525 (0.460–0.599)	0%	< 0.001	47.5 (40.1–54.0)	
Gamma (partial vaccination)							
	All	2	0.594 (0.269–1.311)	95%	0.197	40.6 (–31.1–73.1)	
Beta/Gamma (full vaccination)							
	All	15	0.293 (0.215–0.401)	88%	< 0.001	70.7 (59.9–78.5)	
Vaccine type	mRNA vaccines	10	0.217 (0.154–0.306)	81%	< 0.001	78.3 (69.4–84.6)	0.042^a
	<i>Non-mRNA vaccines</i>	5	0.527 (0.430–0.646)	15%	< 0.001	47.3 (35.4–57.0)	
Beta/Gamma (partial vaccination)							
	All	10	0.507 (0.384–0.670)	96%	< 0.001	49.3 (33.0–61.6)	

Delta (full vaccination)							
All		17	0.284 (0.226–0.359)	94%	< 0.001	71.6 (64.1–77.4)	
Study design	RCT	1	0.348 (0.170–0.669)	–	0.003	65.2 (33.1–83.0)	0.256
	Case-control	10	0.252 (0.182–0.347)	94%	< 0.001	74.8 (65.3–81.8)	
	Cohort	6	0.338 (0.235–0.487)	95%	< 0.001	66.2 (51.3–76.5)	
Vaccine type	mRNA vaccines	11	0.244 (0.169–0.351)	96%	< 0.001	75.6 (64.9–83.1)	0.124
	Non-replicating vector vaccine	4	0.356 (0.316–0.402)	42%	< 0.001	64.4 (59.8–68.4)	
	Inactivated vaccine	2	0.375 (0.225–0.623)	0%	< 0.001	62.5 (37.7–77.5)	
	<i>Non-mRNA vaccines</i>	6	0.354 (0.323–0.387)	7%	< 0.001	64.6 (61.3–67.7)	
Participant	GP	14	0.261 (0.206–0.332)	92%	< 0.001	73.9 (66.8–79.4)	0.119
	Nursing home	1	0.469 (0.433–0.509)	–	< 0.001	53.1 (49.1–56.7)	
	Frontline workers/HCWs	2	0.424 (0.286–0.630)	0%	0.006	57.6 (37.0–71.4)	
Publication	Published	7	0.293 (0.197–0.438)	97%	< 0.001	70.7 (56.2–80.3)	0.841
	Preprint	10	0.280 (0.213–0.368)	87%	< 0.001	72.0 (63.2–78.7)	
Delta (partial vaccination)							
All	Case-control, GP	15	0.474 (0.396–0.567)	90%	< 0.001	52.6 (43.3–60.4)	
Study design	Case-control	12	0.507 (0.421–0.610)	87%	< 0.001	49.3 (39.0–57.9)	0.469
	Cohort	3	0.405 (0.293–0.559)	85%	< 0.001	59.5 (44.1–70.7)	
Vaccine type	mRNA vaccines	9	0.395 (0.306–0.508)	87%	< 0.001	60.5 (49.2–69.4)	0.038
	Non-replicating vector vaccine	5	0.618 (0.507–0.754)	86%	< 0.001	38.2 (24.6–49.3)	
	Inactivated vaccine	1	0.862 (0.452–1.602)	–	0.645	13.8 (–60.2–54.8)	
Participant	GP	14	0.471 (0.391–0.568)	91%	< 0.001	52.9 (43.2–60.9)	0.839
	HCWs	1	0.510 (0.317–0.821)	–	0.006	49.0 (17.9–68.3)	
Publication	Published	5	0.727 (0.659–0.801)	55%	< 0.001	27.3 (19.9–34.1)	< 0.001
	Preprint	10	0.370 (0.309–0.443)	64%	< 0.001	63.0 (55.7–69.1)	

Abbreviations: VE, vaccine effectiveness; HCWs, healthcare workers; LTCH, long term care homes; GP, general population; RCT, randomized controlled trial; ES, effect size.

^aP for interaction between vaccine effectiveness and vaccine type (mRNA vaccines vs. non-mRNA vaccines).

Figure Legends

Figure 1. Forest plot showing vaccine effectiveness of COVID-19 vaccines against Alpha variant. Abbreviations: VE, vaccine effectiveness; CI, confidence interval; RCT, randomized controlled trial.

Figure 2. Forest plot showing vaccine effectiveness of COVID-19 vaccines against Beta/Gamma variants. Abbreviations: VE, vaccine effectiveness; CI, confidence interval; RCT, randomized controlled trial.

Figure 3. Forest plot showing vaccine effectiveness of COVID-19 vaccines against Delta variant. Abbreviations: VE, vaccine effectiveness; CI, confidence interval; RCT, randomized controlled trial.





